Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $38.3852W HIGH $97.59
Volume
299.55 K
Value Traded
60.94 M
Short % Float
16.03%
-7.22%Week
-13.62%1 Month
-29.84%3 Month
-1.99%6 Month
-3.33%5 Year
+177.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.84 B
EPS (TTM)
-1.30
P/E Ratio
-
Ent. Value
2.03 B
Total Shares
29.80 M
Float Shares
27.37 M
Insiders
8.15%
Institutions
102.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ESTA Catalyst Timeline
Dated clinical, regulatory and corporate events for Establishment Labs Holdings Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Establishment Labs Holdings Inc.
3Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How ESTA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Establishment Labs Holdings Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ESTA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Motiva | breast aesthetics | 2023-04-20 | patient compliance: 92.4%; complication rates: no increase in significant issues such as capsular contractureRead More | Establishment Labs Notes Presentation of 3-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2023 New York, NYRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gillin LeslieDirector | Grant/Award | 196 18,594 held | $85.81 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ESTA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1.9 % (26.7 %) | 227.88 M | 2.66 M |
ESTA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ESTA ranks across every disease it competes in
Competitive Position is a premium feature
See how ESTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialESTA News
ESTAEstablishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®
Establishment Labs Holdings Inc. has received FDA approval for an expanded range of Motiva SmoothSilk breast implants. This approval includes 28 new sizes, enhancing the options available for patients in the U.S. market. The move is expected to improve women's health and wellness in breast aesthetics and reconstruction.
Read more →ESTAEstablishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants
Establishment Labs Holdings Inc. presented new clinical data on Breast Tissue Preservation at the 11th World Symposium on Ergonomic Implants. The company also announced extensions to its product lines, Mia® and Preservé™, which now include new sizes and supporting tools. This highlights their commitment to advancing women's health and wellness.
Read more →ESTA▼ -13.4%on this news
Establishment Labs® Reports Second Quarter 2026 Financial Results
Establishment Labs Holdings Inc. reported strong financial results for Q2 2026, with revenues reaching $67.5 million, marking a 31.7% increase from the same period in 2025. The company also experienced a sequential growth of 12.8% from Q1 2026, driven by substantial sales in the United States. These results reflect the company's commitment to enhancing women's health and wellness.
Read more →ESTAEstablishment Labs® to Announce Second Quarter 2026 Financial Results on August 6
Establishment Labs Holdings Inc. will announce its financial results for Q2 2026 on August 6, 2026. The announcement will occur before market opening, followed by a conference call at 8:30 AM ET. This event aims to discuss the company's performance and future outlook.
Read more →ESTAEstablishment Labs® Appoints Taylor Harris to Board of Directors
Establishment Labs has appointed Taylor Harris to its Board of Directors. This strategic move aims to enhance the company's governance and oversight. The appointment reflects the company's commitment to strengthening its leadership team.
Read more →ESTAEstablishment Labs® Added to Membership of U.S. Small-Cap Russell 2000® Index
Establishment Labs has been included in the U.S. Small-Cap Russell 2000 Index, which is expected to enhance the company's visibility and credibility in the market. This addition could potentially attract more investors, reflecting positively on the company's growth prospects. The move signifies recognition of Establishment Labs' position within the small-cap sector.
Read more →ESTA▲ +5%on this news
Establishment Labs Reports First Quarter 2026 Financial Results
Establishment Labs Holdings Inc. reported a 44.7% increase in revenue for Q1 2026, reaching $59.9 million. The company raised its annual revenue guidance due to strong sales in the U.S. and internationally. Notably, adjusted EBITDA was positive for the third consecutive quarter, reflecting improved operational efficiency. However, the company still reported a net loss of $13.4 million, despite a significant reduction from the previous year.
Read more →ESTA▲ +5%on this news
Investor Media Contact Malavika William mwilliam establishmentlabs.com Establishment Labs Reports First Quarter 2026 Financial Results
Establishment Labs Holdings Inc. reported robust financial results for the first quarter of 2026, showcasing a revenue increase of 44.7% to $59.9 million. The company also demonstrated improved operational efficiency with a reduction in losses and the achievement of positive adjusted EBITDA for the third consecutive quarter. Management raised its full-year guidance, anticipating continued growth driven by the successful launch of its minimally invasive platform. The company maintains a strong cash position of $68.1 million as of the quarter's end.
Read more →ESTA▲ +9.9%on this news
Establishment Labs® Refinances Credit Facility
Establishment Labs Holdings Inc. has announced a $300 million senior secured term loan facility with Oaktree Capital Management. This refinancing of existing debt provides the company with additional capital to support its ongoing initiatives in women's health, particularly in breast aesthetics and reconstruction. The move is expected to enhance the company's financial position.
Read more →ESTAEstablishment Labs® to Announce First Quarter 2026 Financial Results on May 6
Establishment Labs Holdings Inc. is set to announce its financial results for Q1 2026 on May 6, 2026. The announcement will occur before market opening, followed by a conference call at 8:30 am ET. This event highlights the company's commitment to transparency and investor relations.
Read more →ESTAEstablishment Labs® Surpasses More Than Five Million Motiva® Devices in Market
Establishment Labs has announced that it has surpassed five million Motiva devices sold in the market. This achievement highlights the company's growth and the increasing acceptance of its innovative products. The milestone indicates a robust demand for Motiva devices, which are designed for aesthetic and reconstructive purposes.
Read more →ESTA▲ +6.3%on this news
Establishment Labs Announces Leadership Transition to Support Next Phase of Growth
Establishment Labs Holdings Inc. announced a leadership transition, promoting Cassandra Harris to CFO while Raj Denhoy shifts to Senior VP of Global Strategy. This change is intended to support the company's growth initiatives and operational momentum. Harris, a seasoned financial executive, expressed her commitment to advancing the company's mission in women's health.
Read more →ESTA▲ +6.3%on this news
Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
Establishment Labs Holdings Inc. reported strong financial results for Q4 2025, with total revenue reaching $64.6 million, up from $44.5 million in Q4 2024. The company highlighted robust demand for its Preservé product and anticipates continued growth, projecting over 25% topline growth for 2026 and 2027. Despite a net loss of $3.9 million, the company achieved positive adjusted EBITDA and is on track for positive cash flow in 2026.
Read more →ESTAEstablishment Labs to Present at TD Cowen's 46th Annual Health Care Conference
Establishment Labs Holdings Inc. will present at TD Cowen's 46th Annual Health Care Conference on March 2, 2026. CEO Peter Caldini and CFO Raj Denhoy will participate in a fireside chat, which will be available via live webcast. The company is recognized for its commitment to women's health through innovative breast aesthetic and reconstruction solutions.
Read more →ESTAEstablishment Labs to Announce Fourth Quarter 2025 Financial Results on February 24
Establishment Labs Holdings Inc. plans to announce its financial results for Q4 2025 on February 24, 2026, before the market opens. A conference call will follow at 8:30 am ET to discuss these results. The company focuses on women's health, offering advanced solutions in breast aesthetics and reconstruction.
Read more →ESTAEstablishment Labs to Present at 44th Annual J.P. Morgan Healthcare Conference
Establishment Labs Holdings Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Peter Caldini and CFO Raj Denhoy will discuss the company's advancements in women's health and breast aesthetics. A live webcast will be available on the investor relations website, with archived versions to follow.
Read more →ESTAEstablishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
Establishment Labs announced preliminary unaudited financial results for the fourth quarter and fiscal year 2025, expecting revenues between $64.0 million and $65.0 million for the quarter. For the full year, the company anticipates revenues in the range of $210.5 million to $211.5 million, indicating a growth of about 27% compared to 2024. The company also reported an increase in cash position and expressed optimism for continued growth into 2026, although the results remain subject to audit.
Read more →ESTAEstablishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction
Establishment Labs has submitted its Motiva implants for FDA approval in primary and revision breast reconstruction. This follows their previous approval for breast augmentation in 2024. The implants are designed to improve patient outcomes with innovative features that adapt to body movements. The company aims to enhance women's health and wellness through advanced technology in breast reconstruction.
Read more →ESTA▼ -14%on this news
Establishment Labs Reports Second Quarter 2025 Financial Results
Establishment Labs Holdings Inc. announced financial results for Q2 2025, reporting a revenue of $51.3 million, a 16.3% increase year-over-year. The company raised its revenue guidance for 2025 to between $208 million and $212 million, driven by robust Motiva sales in the U.S. Despite these gains, the company reported a loss from operations of $14.1 million, larger than in the same quarter last year. CEO Peter Caldini emphasized ongoing sales momentum and growth prospects in the U.S. and internationally.
Read more →About Establishment Labs Holdings Inc.
HeadquartersBUILDING B15 AND 25 COYOL FREE ZONE, ALAJUELA, G2, 20101
BIOPHARMAWATCH ELITE PLUS
Trade the next ESTA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime